Darnitsa Donated 5.25 mln. Doses of Potassium Iodide-125-Darnitsa to the Ministry of Health

Currently, an important issue is the state’s readiness for a potential radiation threat. Given all the challenges, Darnitsa Pharmaceutical Company continues its active cooperation with the Ministry of Health of Ukraine and the National Security and Defense Council of Ukraine to protect Ukrainians from radiation. In the shortest possible time the company launched and registered a new drug “Potassium Iodide-125-Darnitsa”.

The drug was created in accordance with the regulations on iodine prophylaxis in the event of a radiation accident (Order of the Ministry of Health of Ukraine No. 408 dated March 09, 2021).

Potassium iodide is used to protect the thyroid gland from the accumulation of radiation. The risk of radiation damage to the thyroid gland can be reduced or even prevented with the timely iodine prophylaxis. The optimal effect of iodine prophylaxis is achieved by preventive administration of potassium iodide 6 hours or less before or simultaneously with the intake of radioactive isotopes of iodine or entering the contaminated area. Administration of potassium iodide 6 hours after entering the contaminated area with radioactive isotopes of iodine leads to a 2-fold reduction in the radiation dose, and if it is taken after 24 hours - there will be almost no protective effect. A single dose of potassium iodide provides protection for about 24 hours. A prophylactic dose of potassium iodide should be taken only after an official notification of the threat of the emission from the state and the need for iodine prophylaxis.

In total, to protect Ukrainians, Darnitsa has produced 6.71 million doses of Potassium Iodide-125-Darnytsa, which allows for iodine prophylaxis, if necessary, for more than 6 million people. From this batch, Darnitsa donated 5.25 million doses worth UAH 69 million to the Public Health Center of the Ministry of Health of Ukraine. In May, the company plans to produce another 1.5 million doses of Potassium Iodide-125-Darnitsa.

“During the war, the effective interaction between the domestic pharmaceutical business and the state is the key to the national security. Thanks to the cooperation with the Ministry of Health and the National Security and Defense Council, Darnitsa has launched a new drug “Potassium Iodide-125-Darnitsa”, which complies with the regulations of the Ministry of Health on iodine prophylaxis in case of radiation exposure,” said Dmytro Shymkiv, Chairman of the Board of Directors of Darnitsa Group.

Background Information

Darnitsa Pharmaceutical Company PrJSC was founded in 1930. Since 1998, Darnitsa has been the leader in Ukraine in terms of production of medicine by volume. The strategic areas of the portfolio development include cardiology, neurology, pain management.

* Potassium Iodide MA UA/19348/01/01, be sure to read the instructions before administration.

** by production volumes in physical terms, according to Proxima Research

The information is intended exclusively for distribution in specialized publications intended for medical institutions and physicians